本发明公开了KTN1AS1的抑制剂在制备治疗膀胱癌药物中的应用.本发明研究表明,KTN1AS1在BUC细胞及组织中明显上调并与患者预后呈负相关,敲除和上调KTN1AS1的表达分别能增强或抑制体外和体内BUC细胞的增殖,并分别抑制或促进体外和体内细胞凋亡;此外,我们证明上调的KTN1AS1能募集EP300到KTN1启动子,激活KTN1表达,并通过...
本发明公开了KTN1‑AS1的抑制剂在制备治疗膀胱癌药物中的应用。本发明研究表明,KTN1‑AS1在BUC细胞及组织中明显上调并与患者预后呈负相关,敲除和上调KTN1‑AS1的表达分别能增强或抑制体外和体内BUC细胞的增殖,并分别抑制或促进体外和体内细胞凋亡;此外,我们证明上调的KTN1‑AS1能募集EP300到KTN1启动子,激活KT...
In conclusion, KTN1-AS1, induced by SOX2, acts as a tumor-promoting gene and may serve as a potential therapeutic and prognostic biomarker for ESCC.doi:10.1038/s41598-022-24743-zLiying.ChenLaboratory of Pathology, Hebei Cancer Institute, The Fourth Hospital of Hebei Medical University, Jiankang...
KTN1-AS1miR-505-3pinvasionGlioblastoma (GBM) is one of the most prevalent and aggressive central nervous tumors with high mobility and mortality. The prognosis of patients with GBM is poor. It is therefore essential to explore the therapeutic strategies for the treatment of GBM. Previous studies...
Furthermore, KTN1AS1 knockdown decreased the viability and invasive ability of glioma cells invitro and invivo. In addition, high level of KTN1AS1 was correlated with poor prognosis in TCGA GBM database. Furthermore, microRNA5053p (miR5053p) was a promising target of KTN1AS1, and the ...
The KTN1-AS1 and miR-153-3p combination can accurately diagnose HNSCC. Conclusion: The KTN1-AS1 and miR-153-3p combination could be a valuable diagnostic and prognostic predictor for HNSCC.Jiang, YingyingWu, KunCao, WeiXu, QinWang, XuQin, XingWang, XiaoningLi, YanZhang, JianjunChen, Want...